Oleandomycin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Oleandomycin
- DrugBank Accession Number
- DB11442
- Background
Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 687.868
Monoisotopic: 687.419376408 - Chemical Formula
- C35H61NO12
- Synonyms
- Amimycin
- Landomycin
- Matromycin
- Oleandomycin
- Oleandomycine
- Oleandomycinum
- Romicil
- External IDs
- PA 775
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The metabolism of Abemaciclib can be decreased when combined with Oleandomycin. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Oleandomycin. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Oleandomycin. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Oleandomycin. Albendazole The metabolism of Albendazole can be decreased when combined with Oleandomycin. Alectinib The metabolism of Alectinib can be decreased when combined with Oleandomycin. Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Oleandomycin. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Oleandomycin. Alpelisib The metabolism of Alpelisib can be decreased when combined with Oleandomycin. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Oleandomycin. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Oleandomycin hydrochloride 0SEZ96A40Y 6696-47-5 CWYHZGJSHPPEHY-UOBLTHIJSA-N Oleandomycin phosphate 8681H0C27P 7060-74-4 RLPCJGKQKFMBEI-UOBLTHIJSA-N
Categories
- ATC Codes
- J01RA08 — Tetracycline and oleandomycin
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Lactones
- Macrolides
- Macrolides, Lincosamides and Streptogramins
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminoglycosides
- Alternative Parents
- Macrolides and analogues / O-glycosyl compounds / Oxanes / Monosaccharides / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Ketones show 9 more
- Substituents
- 1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteropolycyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester show 21 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- oleandomycins (CHEBI:16869) / Macrolides and lactone polyketides, Macrolides (C01946) / Macrolides and lactone polyketides (LMPK04000007)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P8ZQ646136
- CAS number
- 3922-90-5
- InChI Key
- RZPAKFUAFGMUPI-QESOVKLGSA-N
- InChI
- InChI=1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1
- IUPAC Name
- (3R,5R,6S,7R,8R,11R,12S,13R,14S,15S)-14-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-6-hydroxy-12-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,8,11,13,15-hexamethyl-1,9-dioxaspiro[2.13]hexadecane-4,10-dione
- SMILES
- CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O
References
- General References
- Authors unspecified: Oleandomycin. Can Med Assoc J. 1957 Mar 15;76(6):493. [Article]
- Authors unspecified: OLEANDOMYCIN phosphate. J Am Med Assoc. 1958 Oct 25;168(8):1011-2. [Article]
- DIMMLING T: [Oleandomycin-triacetate, a new oleandomycin derivative]. Arzneimittelforschung. 1959 Apr;9(4):236-41. [Article]
- KUNZER W, BECK B: [Oleandomycin & blood coagulation]. Munch Med Wochenschr. 1958 Sep 12;100(37):1391-2. [Article]
- SULI M: [SENSITIVITY TO OLEANDOMYCIN]. Alergia. 1964 Nov;12:55-8. [Article]
- Lightbown JW, Kogut M, Mussett MV: [International formula for oleandomycin]. Bol Oficina Sanit Panam. 1967 Feb;62(2):157-65. [Article]
- SOLIGNAC H: [A new antibiotic: oleandomycin]. Sem Med Prof Med Soc. 1958 Nov 20;34(40):1168-70. [Article]
- CITTERIO C, CORIANDOLI EM: [Rectal absorption of oleandomycin]. Boll Soc Ital Biol Sper. 1959 Aug 31;35:976-7. [Article]
- DE MORAES F, PATTO O: [Oleandomycin and bone infections]. Acta Orthop Belg. 1959 Sep-Oct;25:635-56. [Article]
- Ross S: Erythromycin, oleandomycin and triacetyloleandomycin. Pediatr Clin North Am. 1968 Feb;15(1):119-29. [Article]
- External Links
- KEGG Compound
- C01946
- ChemSpider
- 10190754
- BindingDB
- 234401
- 7629
- ChEBI
- 16869
- ChEMBL
- CHEMBL606258
- ZINC
- ZINC000085432018
- Wikipedia
- Oleandomycin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.407 mg/mL ALOGPS logP 1.46 ALOGPS logP 2.98 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 12.67 Chemaxon pKa (Strongest Basic) 9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 12 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 162.68 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 173.69 m3·mol-1 Chemaxon Polarizability 73.87 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
1. DetailsCytochrome P450 3A4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created at February 25, 2016 18:48 / Updated at February 21, 2021 18:53